- Home
- JANX vs GERN Comparison
JANX vs GERN Comparison
Compare JANX & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JANX
- GERN
- Stock Information
- Founded
- JANX 2017
- GERN 1990
- Country
- JANX United States
- GERN United States
- Employees
- JANX N/A
- GERN N/A
- Industry
- JANX Biotechnology: Pharmaceutical Preparations
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- JANX Health Care
- GERN Health Care
- Exchange
- JANX Nasdaq
- GERN Nasdaq
- Market Cap
- JANX 2.9B
- GERN 2.5B
- IPO Year
- JANX 2021
- GERN 1996
- Fundamental
- Price
- JANX $50.31
- GERN $4.07
- Analyst Decision
- JANX Strong Buy
- GERN Strong Buy
- Analyst Count
- JANX 11
- GERN 10
- Target Price
- JANX $66.36
- GERN $6.95
- AVG Volume (30 Days)
- JANX 635.6K
- GERN 10.2M
- Earning Date
- JANX 11-06-2024
- GERN 11-07-2024
- Dividend Yield
- JANX N/A
- GERN N/A
- EPS Growth
- JANX N/A
- GERN N/A
- EPS
- JANX N/A
- GERN N/A
- Revenue
- JANX $13,049,000.00
- GERN $29,480,000.00
- Revenue This Year
- JANX $66.30
- GERN $30,930.80
- Revenue Next Year
- JANX N/A
- GERN $315.72
- P/E Ratio
- JANX N/A
- GERN N/A
- Revenue Growth
- JANX 54.12
- GERN 9199.68
- 52 Week Low
- JANX $7.79
- GERN $1.64
- 52 Week High
- JANX $65.60
- GERN $5.34
- Technical
- Relative Strength Index (RSI)
- JANX 48.44
- GERN 50.64
- Support Level
- JANX $45.95
- GERN $3.60
- Resistance Level
- JANX $49.74
- GERN $3.86
- Average True Range (ATR)
- JANX 2.80
- GERN 0.21
- MACD
- JANX -0.77
- GERN 0.01
- Stochastic Oscillator
- JANX 37.81
- GERN 52.22
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to treat patients suffering from cancer.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.